

40. (Amended) A diagnostic and/or purification device comprising at least [one element selected from the group consisting of] the fragment of Claim 31, or the conformational epitope of Claim 35[, inhibitor of Claim 37 and the anti-inhibitor of Claim 38] and an acceptable pharmaceutical vehicle.

B1
CMT
41. (Amended) A method for therapeutic treatment/prevention of an immune disorder induced by inhibitors of factor VIII, inhibitors of the binding factor VIII to the von Willebrand factor or inhibitors of the binding of factor VIII to membrane phospholipids, said method comprising administering the pharmaceutical composition [of Claim 39]comprising at least the fragment of Claim 31, or the conformational epitope of Claim 35 and an acceptable pharmaceutical vehicle to a patient presently or potentially having the immune disorder in an amount effective to treat or prevent the immune disorder.

REMARKS

The Communication from the Examiner stated that the above applications contains 11 different inventions as defined below and required an election of the invention to be examined. The Groups were as follows:

Group I consisting of claims 31-36 and 39, drawn to a polypeptide and a pharmaceutical composition, Group II consisting of Claims 37 and 39, drawn to an antibody as an inhibitor of factor VIII and a pharmaceutical composition, Group III consisting of Claims 38 and 39, drawn to an anti-idiotypic antibody as anti-inhibitor of factor VIII and a pharmaceutical composition, Group IV consisting of Claim 40, drawn to a diagnostic and/or purification device comprising a polypeptide, Group V consisting of Claim 40, drawn to a diagnostic and/or purification device comprising an inhibitor of factor VIII, Group VI consisting of Claim 40, drawn to a diagnostic and/or purification device comprising an anti-inhibitor of factor VIII, Group VII consisting of Claim 41, drawn to a method for therapeutic treatment/prevention administering a polypeptide, Group VIII consisting of Claim 41, drawn to a method for therapeutic treatment/prevention administering an antibody, Group IX consisting of Claim 41, drawn to a method for therapeutic treatment/prevention administering an anti-idiotypic antibody, Group X consisting of Claim 42, drawn to a method for obtaining an inhibitor of factor VIII, and Group XI consisting of Claim 43, drawn to a method for identifying anti-inhibitors of factor VIII.

In response to the Restriction Requirement, Applicants elect Group I, Claims 31-36, and 39, drawn to a polypeptide and a pharmaceutical composition. This election is made without

traverse. Claims 37-38 and 43 have been canceled as drawn to a non-elected invention. However, the remaining claims, Claims 39-42 are all ultimately dependent on the Group I claims. Accordingly, rejoinder of these claims, belonging to Groups IV, VII, and X, is respectfully requested upon allowance of the elected Group I claims.

Conclusion

If any clarification is needed, the Examiner is respectfully invited to contact the undersigned attorney at the telephone number appearing below.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 20 Nov. 2000

By: Daniel Altman

Daniel E. Altman
Registration No. 34,115
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404